PGNY
Progyny, Inc.
PGNY's fundamentals are strong and it looks cheap: trading at 34x earnings, below its usual 43x. Analysts expect strong earnings growth.
PGNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
PGNY's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
PGNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $36.58 | — |
| Cheap | 32x | $34.56 | -5.5% |
| Current | 34x | $36.58 | — |
| Fair | 43x | $46.46 | +27% |
| Expensive | 91x | $98.79 | +170% |
Historical ranges are pointers, not guarantees.
PGNY's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
PGNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PGNY, with profitability improving.
PGNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.54 | +41% |
| Q3 2026 | $1.09 | +73% |
| Q2 2026 | $0.92 | +56% |
| Q1 2026 | $0.77 | +35% |
| Q4 2025 | $0.65 | +14% |
| Q3 2025 | $0.63 | +8.6% |
| Q2 2025 | $0.59 | -6.3% |
| Q1 2023 | $0.43 | -23% |
| Q4 2022 | $0.30 | -55% |
PGNY earned $1.09 per share over the past year, up 73% from the year before.
PGNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $341.3M | +8.9% |
| Q2 2026 | $350.5M | +5.3% |
| Q1 2026 | $328.5M | +1.4% |
| Q4 2025 | $318.4M | +6.7% |
| Q3 2025 | $313.3M | +9.3% |
| Q2 2025 | $332.9M | +9.5% |
| Q1 2025 | $324M | +17% |
| Q4 2024 | $298.4M | +11% |
PGNY's revenue has grown year over year every quarter since late 2020: $341M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +3.4 points |
| Q2 2026 | 11% | +4.1 points |
| Q1 2026 | 11% | +3.3 points |
| Q4 2025 | 4.8% | -0.5 points |
| Q3 2025 | 6.9% | +2.5 points |
| Q2 2025 | 7.3% | +0.5 points |
| Q1 2025 | 7.5% | +0.8 points |
| Q4 2024 | 5.3% | +0.2 points |
PGNY's operating margin was 10% last quarter, up 3.4 points from the same quarter a year ago.
PGNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.2M | +2.7% |
| Q2 2026 | $44.2M | -12% |
| Q1 2026 | $39.6M | -16% |
| Q4 2025 | $48.6M | -3.3% |
| Q3 2025 | $46M | +7.6% |
| Q2 2025 | $50.2M | -10% |
| Q1 2025 | $47M | +89% |
| Q4 2024 | $50.3M | +36% |
PGNY generated $180M in free cash flow over the past year, down 7.1% from the year before.
PGNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -969K shares |
| 1 year | -10% | -9.1M shares |
| 3 years | -20% | -19.7M shares |
| 5 years | -19% | -19.2M shares |
| Available history | +26% | +17M shares |
PGNY has 81M diluted shares, down 10% from a year ago, with $313M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $82.8M |
| Q2 2026 | $30M |
| Q1 2026 | $118.6M |
| Q4 2025 | $81.7M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $55.1M |
PGNY spent $313M buying back its own shares over the past year, about six times what it spent the year before.
PGNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -1.3x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -1.4x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
PGNY has more cash than debt.
PGNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
PGNY's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
PGNY PE vs Healthcare Sector
| Metric | PGNY | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 21 | 29 | 8 pts below |
PGNY is trading at 34x earnings, a 30% premium to the Healthcare sector's median of 26x.
PGNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.4 | 25% above |
| 20 week MA | $28.8 | 27% above |
| 50 week MA | $25.0 | 46% above |
| 100 week MA | $23.3 | 57% above |
| 200 week MA | $27.3 | 34% above |
PGNY has climbed back above all five of its weekly moving averages, and it's now 34% above its 200-week average.
PGNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.0 | $42.2 | +51% |
| 2021 | $42.2 | $51.5 | +22% |
| 2022 | $51.5 | $30.8 | -40% |
| 2023 | $30.8 | $37.2 | +21% |
| 2024 | $37.2 | $16.9 | -55% |
| 2025 | $16.9 | $25.8 | +53% |
| 2026 YTD | $25.8 | $36.6 | +42% |
PGNY has finished higher in four of the last six years, two of them by more than 50%. It's up 42% so far in 2026.